Logo

RMD

ResMed Inc.

RMD

ResMed Inc. • NYSE
$255.83 ▲ 0.31% (+0.79)
Market Cap $37.49 B
52w High $293.81
52w Low $199.92
Dividend Yield 2.26%
P/E 26.19
Volume 335.09K
Outstanding Shares 146.55M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $1.336B ▼ $374.283M ▲ $348.536M ▼ 26.096% ▼ $2.38 ▼ $503.284M ▼
Q4-2025 $1.348B ▲ $365.527M ▲ $379.705M ▲ 28.168% ▼ $2.59 ▲ $532.341M ▲
Q3-2025 $1.292B ▲ $340.139M ▲ $365.041M ▲ 28.26% ▲ $2.49 ▲ $469.603M ▼
Q2-2025 $1.282B ▲ $334.033M ▲ $344.622M ▲ 26.88% ▲ $2.35 ▲ $479.012M ▲
Q1-2025 $1.225B $329.907M $311.355M 25.427% $2.12 $442.709M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $1.384B ▲ $8.308B ▲ $2.187B ▼ $6.121B ▲
Q4-2025 $1.209B ▲ $8.174B ▲ $2.207B ▲ $5.968B ▲
Q3-2025 $944.842M ▲ $7.567B ▲ $2.021B ▲ $5.546B ▲
Q2-2025 $521.944M ▲ $7.141B ▼ $1.888B ▼ $5.253B ▲
Q1-2025 $426.361M $7.222B $2.027B $5.195B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $348.536M ▼ $457.321M ▼ $-52.578M ▲ $-230.274M ▼ $174.398M ▼ $414.356M ▼
Q4-2025 $379.705M ▲ $538.766M ▼ $-133.713M ▼ $-163.887M ▼ $276.739M ▼ $508.181M ▼
Q3-2025 $365.041M ▲ $578.661M ▲ $-31.786M ▲ $-144.071M ▲ $410.767M ▲ $554.873M ▲
Q2-2025 $344.622M ▲ $308.623M ▼ $-36.692M ▼ $-147.538M ▲ $95.583M ▼ $289.746M ▼
Q1-2025 $311.355M $325.538M $2.146M $-150.757M $188M $305.931M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q1-2026
Residential Care Software
Residential Care Software
 $0 ▲$160.00M ▲$160.00M ▲$170.00M ▲
Sleep And Respiratory
Sleep And Respiratory
 $1.07Bn ▲$1.07Bn ▲$1.13Bn ▲$1.17Bn ▲
Software As Service
Software As Service
 $150.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement ResMed’s income statement shows a business that has grown steadily and become more profitable over the past five years. Sales have climbed each year, and profits have risen faster than revenue, which suggests good cost control and strong pricing power. Profit margins look healthy for a medical device company, and recent years show especially strong bottom-line improvement. Overall, the company appears to be converting its market leadership into solid, consistent earnings growth rather than one‑off gains.

Balance Sheet

Balance Sheet The balance sheet looks robust and has strengthened over time. Total assets and shareholder equity have built up steadily, indicating that the company is reinvesting and growing on a solid capital base. Debt is present but moderate relative to the size of the business, and recent growth in cash balances gives ResMed more financial flexibility and a cushion against shocks. This combination points to a conservative, resilient financial structure rather than an aggressive, highly leveraged one.

Cash Flow

Cash Flow Cash flow is a clear bright spot. Operating cash generation has improved meaningfully in recent years, and most of that cash is flowing through to free cash flow because the business does not require heavy spending on equipment and facilities. This strong cash profile supports ongoing investment in innovation, potential acquisitions, and returns to shareholders, while also giving management room to navigate any downturns. The consistency between profits and cash flow also suggests earnings quality is generally solid.

Competitive Edge

Competitive Edge ResMed holds a leading position in sleep and respiratory care, supported by a wide installed base of devices, masks, and software. Its brand is well trusted by patients and clinicians, and its digital platforms create switching costs for both users and providers. A large patent portfolio and strong history of defending its technology add another layer of protection. The recall issues at a major competitor have further strengthened its position, although that benefit may normalize over time as rivals recover and new entrants emerge.

Innovation and R&D

Innovation and R&D Innovation is central to ResMed’s strategy. The company has steadily upgraded its core devices and masks while building a connected digital ecosystem that links patients, providers, and data in real time. Its use of cloud software, analytics, and now generative AI differentiates its offering and can deepen customer relationships. Looking ahead, expansion into adjacent conditions like COPD and insomnia, tighter integration with wearables, and easier at‑home diagnosis all represent growth opportunities—but they also require sustained investment and careful execution.

Summary

ResMed combines consistent growth, strong profitability, and solid cash generation with a fortified balance sheet, giving it financial resilience. Its competitive edge rests on a mix of trusted hardware, sticky software platforms, deep data, and extensive intellectual property, all operating in a market with favorable long‑term health trends. At the same time, the company is pushing into more digital and AI‑driven health solutions, which could broaden its opportunity but also introduce new technology, regulatory, and integration risks. Overall, the picture is of a financially strong, innovation‑led healthcare company with a durable position in its niche and meaningful execution and competitive dynamics to monitor over time.

NEWS

October 30, 2025 · 4:05 PM UTC

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

Read more

October 9, 2025 · 4:05 PM UTC

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

Read more

September 16, 2025 · 4:05 PM UTC

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025

Read more

September 3, 2025 · 4:15 PM UTC

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

Read more